|
Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest
RECRUITINGN/ASponsored by Medisch Spectrum Twente
Actively Recruiting
PhaseN/A
SponsorMedisch Spectrum Twente
Started2024-03-12
Est. completion2026-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06048796
Summary
The objective of this study is to estimate the feasibility and safety of early weaning from ICU treatment in patients after cardiac arrest and an early (\< 12 h) favourable EEG pattern (indicating no or mild postanoxic encephalopathy).
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation. * Age 18 years or older. * Continuous EEG measurement started within 12 hours after cardiac arrest. * Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019). * Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern. * Written informed consent (deferred). Exclusion Criteria: * A known history of another medical condition with limited life expectancy (\<6 months). * Any progressive brain illness, such as a brain tumour or neurodegenerative disease. * Pre-admission Glasgow Outcome Scale Extended score of 4 or lower. * Reason other than neurological condition to continue sedation and/or ventilation. * Follow-up impossible due to logistic reasons.
Conditions3
Heart ArrestHeart DiseaseHypoxia-Ischemia, Brain
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorMedisch Spectrum Twente
Started2024-03-12
Est. completion2026-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT06048796